Skip to content

Study · Animal study (in vivo) · rat · 2006

5 results

An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157.

Petrovic I, Dobric I, Drvis P, Shejbal D, Brcic L, Blagaic AB, Batelja L, Kokic N, Tonkic A, Mise S, Baotic T, Staresinic M and 6 more

Show all authors

Radic B, Jakir A, Vuksic T, Anic T, Seiwerth S, Sikiric P

Journal of pharmacological sciences1 Nov 2006Cited by 22 (Europe PMC)

PMID17116974 (opens in a new tab)DOI10.1254/jphs.fp0060070 (opens in a new tab)PepBankPUB-17116974
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with prolonged esophagitis, BPC‑157 recovered esophagitis, macroscopically and microscopically.

    In plain wordsIn rats with long-lasting esophagitis, BPC‑157 reduced the inflammation of the esophagus.

    Peptide
    BPC-157
    Outcome
    DecreaseEsophagitis
    Study

    ratn: not reported in source

    Prolonged esophagitis with sphincter failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 micro g/kg; 0.16 micro g/ml in drinking water · intraperitoneal, drinking water or intragastricAs given in this study (rat).

    Source sentences

    Summary
    This treatment recovers i) esophagitis (macroscopically and microscopically, at either region or investigated time period) and ii) pressure in both sphincters (cmH2O).
    1 context sentence
    Summary · context
    Throughout the esophagitis experiment, BPC 157 was given at either 10 micro g/kg, i.p., once a day (last application 24 h before assessment) or alternatively, it was given continuously in drinking water at 0.16 micro g/ml (12 ml/rat).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with prolonged esophagitis and failed sphincters, BPC‑157 recovered pressure in the lower esophageal sphincter.

    In plain wordsIn rats with long-lasting esophagitis, BPC‑157 restored pressure in the muscle at the lower end of the esophagus.

    Peptide
    BPC-157
    Outcome
    IncreaseLower esophageal sphincter pressure in esophagitis
    Study

    ratn: not reported in source

    Prolonged esophagitis with sphincter failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 micro g/kg; 0.16 micro g/ml in drinking water · intraperitoneal, drinking water or intragastricAs given in this study (rat).

    Source sentences

    Summary
    This treatment recovers i) esophagitis (macroscopically and microscopically, at either region or investigated time period) and ii) pressure in both sphincters (cmH2O).
    1 context sentence
    Summary · context
    Throughout the esophagitis experiment, BPC 157 was given at either 10 micro g/kg, i.p., once a day (last application 24 h before assessment) or alternatively, it was given continuously in drinking water at 0.16 micro g/ml (12 ml/rat).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with prolonged esophagitis and failed sphincters, BPC‑157 recovered pressure in the pyloric sphincter.

    In plain wordsIn rats with long-lasting esophagitis, BPC‑157 restored pressure in the stomach outlet muscle.

    Peptide
    BPC-157
    Outcome
    IncreasePyloric sphincter pressure in esophagitis
    Study

    ratn: not reported in source

    Prolonged esophagitis with sphincter failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 micro g/kg; 0.16 micro g/ml in drinking water · intraperitoneal, drinking water or intragastricAs given in this study (rat).

    Source sentences

    Summary
    This treatment recovers i) esophagitis (macroscopically and microscopically, at either region or investigated time period) and ii) pressure in both sphincters (cmH2O).
    1 context sentence
    Summary · context
    Throughout the esophagitis experiment, BPC 157 was given at either 10 micro g/kg, i.p., once a day (last application 24 h before assessment) or alternatively, it was given continuously in drinking water at 0.16 micro g/ml (12 ml/rat).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats, BPC‑157 increased lower esophageal sphincter pressure.

    In plain wordsIn healthy rats, BPC‑157 raised the pressure in the muscle at the lower end of the esophagus.

    Peptide
    BPC-157
    Outcome
    IncreaseLower esophageal sphincter pressure in normal rats
    Study

    ratn: not reported in source

    Normal rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect of BPC 157 is specific because in normal rats, it increases lower esophageal sphincter-pressure, but decreases pyloric sphincter-pressure.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats, BPC‑157 decreased pyloric sphincter pressure.

    In plain wordsIn healthy rats, BPC‑157 lowered the pressure in the stomach outlet muscle.

    Peptide
    BPC-157
    Outcome
    DecreasePyloric sphincter pressure in normal rats
    Study

    ratn: not reported in source

    Normal rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect of BPC 157 is specific because in normal rats, it increases lower esophageal sphincter-pressure, but decreases pyloric sphincter-pressure.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.